264 related articles for article (PubMed ID: 23109706)
1. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
Weischer M; Nordestgaard BG; Pharoah P; Bolla MK; Nevanlinna H; Van't Veer LJ; Garcia-Closas M; Hopper JL; Hall P; Andrulis IL; Devilee P; Fasching PA; Anton-Culver H; Lambrechts D; Hooning M; Cox A; Giles GG; Burwinkel B; Lindblom A; Couch FJ; Mannermaa A; Grenaker Alnæs G; John EM; Dörk T; Flyger H; Dunning AM; Wang Q; Muranen TA; van Hien R; Figueroa J; Southey MC; Czene K; Knight JA; Tollenaar RA; Beckmann MW; Ziogas A; Christiaens MR; Collée JM; Reed MW; Severi G; Marme F; Margolin S; Olson JE; Kosma VM; Kristensen VN; Miron A; Bogdanova N; Shah M; Blomqvist C; Broeks A; Sherman M; Phillips KA; Li J; Liu J; Glendon G; Seynaeve C; Ekici AB; Leunen K; Kriege M; Cross SS; Baglietto L; Sohn C; Wang X; Kataja V; Børresen-Dale AL; Meyer A; Easton DF; Schmidt MK; Bojesen SE
J Clin Oncol; 2012 Dec; 30(35):4308-16. PubMed ID: 23109706
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of breast cancer associated with CHEK2*1100delC.
Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
[TBL] [Abstract][Full Text] [Related]
3. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
Näslund-Koch C; Nordestgaard BG; Bojesen SE
J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
[TBL] [Abstract][Full Text] [Related]
4. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
[TBL] [Abstract][Full Text] [Related]
5. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.
Fletcher O; Johnson N; Dos Santos Silva I; Kilpivaara O; Aittomäki K; Blomqvist C; Nevanlinna H; Wasielewski M; Meijers-Heijerboer H; Broeks A; Schmidt MK; Van't Veer LJ; Bremer M; Dörk T; Chekmariova EV; Sokolenko AP; Imyanitov EN; Hamann U; Rashid MU; Brauch H; Justenhoven C; Ashworth A; Peto J
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):230-4. PubMed ID: 19124502
[TBL] [Abstract][Full Text] [Related]
6. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
de Bock GH; Mourits MJ; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
Int J Gynecol Cancer; 2006; 16 Suppl 2():552-5. PubMed ID: 17010071
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
[TBL] [Abstract][Full Text] [Related]
8. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
Schmidt MK; Hogervorst F; van Hien R; Cornelissen S; Broeks A; Adank MA; Meijers H; Waisfisz Q; Hollestelle A; Schutte M; van den Ouweland A; Hooning M; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Arndt V; Bermisheva M; Bogdanova NV; Bolla MK; Brauch H; Brenner H; Brüning T; Burwinkel B; Chang-Claude J; Chenevix-Trench G; Couch FJ; Cox A; Cross SS; Czene K; Dunning AM; Fasching PA; Figueroa J; Fletcher O; Flyger H; Galle E; García-Closas M; Giles GG; Haeberle L; Hall P; Hillemanns P; Hopper JL; Jakubowska A; John EM; Jones M; Khusnutdinova E; Knight JA; Kosma VM; Kristensen V; Lee A; Lindblom A; Lubinski J; Mannermaa A; Margolin S; Meindl A; Milne RL; Muranen TA; Newcomb PA; Offit K; Park-Simon TW; Peto J; Pharoah PD; Robson M; Rudolph A; Sawyer EJ; Schmutzler RK; Seynaeve C; Soens J; Southey MC; Spurdle AB; Surowy H; Swerdlow A; Tollenaar RA; Tomlinson I; Trentham-Dietz A; Vachon C; Wang Q; Whittemore AS; Ziogas A; van der Kolk L; Nevanlinna H; Dörk T; Bojesen S; Easton DF
J Clin Oncol; 2016 Aug; 34(23):2750-60. PubMed ID: 27269948
[TBL] [Abstract][Full Text] [Related]
9. CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls.
Yang Y; Zhang F; Wang Y; Liu SC
Asian Pac J Cancer Prev; 2012; 13(7):3501-5. PubMed ID: 22994785
[TBL] [Abstract][Full Text] [Related]
10. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
[TBL] [Abstract][Full Text] [Related]
11. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.
Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA
Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844
[TBL] [Abstract][Full Text] [Related]
12. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
de Bock GH; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
J Med Genet; 2004 Oct; 41(10):731-5. PubMed ID: 15466005
[TBL] [Abstract][Full Text] [Related]
13. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; ; ; Jakubowska A; Janni W; Jernström H; John EM; Johnson N; Jones ME; Kristensen VN; Kurian AW; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Lux MP; Mannermaa A; Mavroudis D; Mulligan AM; Muranen TA; Nevanlinna H; Nevelsteen I; Neven P; Newman WG; Obi N; Offit K; Olshan AF; Park-Simon TW; Patel AV; Peterlongo P; Phillips KA; Plaseska-Karanfilska D; Polley EC; Presneau N; Pylkäs K; Rack B; Radice P; Rashid MU; Rhenius V; Robson M; Romero A; Saloustros E; Sawyer EJ; Schmutzler RK; Schuetze S; Scott C; Shah M; Smichkoska S; Southey MC; Tapper WJ; Teras LR; Tollenaar RAEM; Tomczyk K; Tomlinson I; Troester MA; Vachon CM; van Veen EM; Wang Q; Wendt C; Wildiers H; Winqvist R; Ziogas A; Hall P; Pharoah PDP; Adank MA; Hollestelle A; Schmidt MK; Hooning MJ
Cancer Med; 2023 Aug; 12(15):16142-16162. PubMed ID: 37401034
[TBL] [Abstract][Full Text] [Related]
14. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.
CHEK2 Breast Cancer Case-Control Consortium
Am J Hum Genet; 2004 Jun; 74(6):1175-82. PubMed ID: 15122511
[TBL] [Abstract][Full Text] [Related]
15. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.
Mellemkjaer L; Dahl C; Olsen JH; Bertelsen L; Guldberg P; Christensen J; Børresen-Dale AL; Stovall M; Langholz B; Bernstein L; Lynch CF; Malone KE; Haile RW; Andersson M; Thomas DC; Concannon P; Capanu M; Boice JD; ; Bernstein JL
Br J Cancer; 2008 Feb; 98(4):728-33. PubMed ID: 18253122
[TBL] [Abstract][Full Text] [Related]
16. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
[TBL] [Abstract][Full Text] [Related]
17. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
18. CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum.
Isinger A; Bhat M; Borg A; Nilbert M
BMC Cancer; 2006 Mar; 6():64. PubMed ID: 16539695
[TBL] [Abstract][Full Text] [Related]
19. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
[TBL] [Abstract][Full Text] [Related]
20. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
